The Future of the Metabolic Syndrome

References

• 1 Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic.  Nature. 2001;  414 782-787
• 2 Hanefeld MLW. Das Metabolische Syndrom.  Dtsch. Gesundh Wesen. 1981;  36 545-551
• 3 Schwarz PE, Reimann M, Li J, Bergmann A, Licinio J, Wong ML, Bornstein SR. The metabolic syndrome – a global challenge for prevention.  Horm Metab Res. 2007;  39 777-780
• 4 Hanefeld M, Ceriello A, Schwarz PE, Bornstein SR. The challenge of the metabolic syndrome.  Horm Metab Res. 2007;  39 625-626
• 5 Hanefeld M, Ceriello A, Schwarz PE, Bornstein SR. The metabolic syndrome – a postprandial disease?.  Horm Metab Res. 2006;  38 435-436
• 6 Schutte AE, Schutte R, Huisman HW, Rooyen JM, Malan L, Olckers A, Malan NT. Classifying Africans with the metabolic syndrome.  Horm Metab Res. 2009;  41 79-85
• 7 Schwarz PE, Muylle F, Valensi P, Hall M. The European perspective of diabetes prevention.  Horm Metab Res. 2008;  40 511-514
• 8 Onyegbutulem HC, H-Onyegbutulem PI, Reimann M, Li J, Bornstein SR, Schwarz PE. Metabolic syndrome in Africa: an emerging perspective.  Horm Metab Res. 2009;  41 75-78
• 9 Rothe U, Müller G, Tselmin S, Odenbach C, Scheuch K, Koch R, Bergmann S, Walter M, Bergmann A, Bornstein SR, Schwarz PE. Prevalence for the cluster of risk factors of the metabolic vascular syndrome in a working population in Germany.  Horm Metab Res. 2009;  41 168-170
• 10 Li J, Bergmann A, Reimann M, Bornstein SR, Schwarz PE. A more simplified Finnish diabetes risk score for opportunistic screening of undiagnosed type 2 diabetes in a German population with a family history of the metabolic syndrome.  Horm Metab Res. 2009;  41 98-103
• 11 Schwarz PE, Li J, Lindstrom J, Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily practice.  Horm Metab Res. 2009;  41 86-97
• 12 Schwarz PE, Schwarz J, Schuppenies A, Bornstein SR, Schulze J. Development of a diabetes prevention management program for clinical practice.  Public Health Rep. 2007;  122 258-263
• 13 Schinner S. Wnt-signalling and the metabolic syndrome.  Horm Metab Res. 2009;  41 159-163
• 14 Paz-Filho GJ, Andrews D, Esposito K, Erol HK, Delibasi T, Wong ML, Licinio J. Effects of leptin replacement on risk factors for cardiovascular disease in genetically leptin-deficient subjects.  Horm Metab Res. 2008;  41 164-167
• 15 Andreev VP, Paz-Filho G, Wong ML, Licinio J. Deconvolution of insulin secretion, insulin hepatic extraction post-hepatic delivery rates and sensitivity during 24-h standardized meals: time course of glucose homeostasis in leptin replacement treatment.  Horm Metab Res. 2008;  41 142-151
• 16 Forst T, Hohberg C, Pfützner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients.  Horm Metab Res. 2009;  41 123-131
• 17 Muller G, Morawietz H. NAD(P)H oxidase and endothelial dysfunction.  Horm Metab Res. 2008;  41 152-158
• 18 von Bibra H, Siegmund T, Ceriello A, Volozhyna M, Schumm-Draeger PM. Optimized postprandial glucose control is associated with improved cardiac/vascular function – comparison of three insulin regimens in well-controlled type 2 diabetes.  Horm Metab Res. 2009;  41 109-115
• 19 Kohnert KD, Vogt L, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, Salzsieder E. Relationships between glucose variability and conventional measures of glycemic control in continuously monitored patients with type 2 diabetes.  Horm Metab Res. 2009;  41 137-141
• 20 Pistrosch F, Schaper F, Passauer J, Koehler C, Bornstein SR, Hanefeld M. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.  Horm Metab Res. 41 104-108

Correspondence